Embedded Files
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science on August 19, 2022, DOI: 10.1126/science.abk0637.
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science on August 19, 2022, DOI: 10.1126/science.abk0637.
"Cognitive heterogeneity in Parkinson's disease: A mechanistic view," by Marc Carceles-Cordon, Dan Weintraub, and Alice Chen-Plotkin can be found here.
"Cognitive heterogeneity in Parkinson's disease: A mechanistic view," by Marc Carceles-Cordon, Dan Weintraub, and Alice Chen-Plotkin can be found here.
This is a review that captures a lot of how we're thinking about the synucleinopathies (Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy). We are actively trying to target many of these mechanisms now.
This is a review that captures a lot of how we're thinking about the synucleinopathies (Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy). We are actively trying to target many of these mechanisms now.
"A-Synuclein conformations in plasma distinguish Parkinson's disease from dementia with Lewy bodies," by George Kannarkat, Rebecca Zack, et al. can be found here.
"A-Synuclein conformations in plasma distinguish Parkinson's disease from dementia with Lewy bodies," by George Kannarkat, Rebecca Zack, et al. can be found here.
This is the preprint. We'll keep you posted on its eventual publication home!
This is the preprint. We'll keep you posted on its eventual publication home!
There are also the things we learned the hard way. And other useful stuff.
Some experiments work out the way that you expect. Some do not. Some projects are publishable. Some are not.
Here is a place we are putting data that we think is valuable, but not publishable. Some of it is negative data (e.g. biomarkers that did not replicate). Some of it is data that is too confusing (e.g. things that are too noisy to translate clinically). Some of it is information that you may just want (e.g. quality control procedures, experience with various assays, slides from talks).
A quick guide to the files you can access below:
(1) MJFF PPMI data-May2015: This is a set of slides showing our data for measures of epidermal growth factor (EGF) and apolipoprotein A1 (ApoA1) in plasma samples from the international Michael J. Fox Foundation Parkinson's Progression marker Initiative cohort. EGF measures vary greatly by clinical site of origin, even with the rigorous standard operative procedures that PPMI uses. In these same samples, ApoA1 measures, in contrast, do not. Bottom line is that from the perspective of biomarker development, some proteins will be better candidates by virtue of their stability to variation in sample collection/storage/processing.
(2) Somalogic Slides: Quality control data from our experience with the Somalogic aptamer platform. The first slide shows the analytes that "failed" quality control (>20% CV across any of three sets of triplicates -- 9 QC samples total = 3 sets x 3 triplicates). The second slide shows whether the three sets of triplicates overlapped with respect to "failures." The third and fourth slides show whether the Somalogic platform performs similarly across space (Penn vs. Boulder) and time (2013 vs. 2015).
(3) Derek Denny Brown lecture slides: These are from Alice's presentation in October 2018 when she was awarded the Derek Denny Brown Award from the American Neurological Association. They provide an overview of what the lab was doing in its first 8 years.
MJFF PPMI data-May2015.pptxSomalogicSlides.pdfTowardsTranslationDDB-NoHidden.pdfGoogle Sites
Report abuse